 Non-Hodgkin Lymphoma Therapeutics Market Insights, Competitive Landscape, and Market Forecast - 2033
Treatment of non-Hodgkin lymphoma is undergoing rapid change, driving healthy growth in the therapeutics market. Increasing disease incidence in aging populations, improved survival, and the arriva... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryTreatment of non-Hodgkin lymphoma is undergoing rapid change, driving healthy growth in the therapeutics market. Increasing disease incidence in aging populations, improved survival, and the arrival of advanced therapies such as CAR T-cell treatments and bispecific antibodies are expanding the range of options available for both aggressive and indolent forms of the disease. The global non-Hodgkin lymphoma therapeutics market is expected to be valued at US$ 16.80 Billion in 2026 and is projected to reach US$ 28.98 Billion by 2033, growing at a CAGR of 8.1% between 2026 and 2033.Market Insights: The therapeutic mix spans monoclonal antibodies, CAR T-cell therapies, BTK inhibitors, and other agents, given through intravenous or subcutaneous routes. Monoclonal antibodies account for around 44.0% of 2026 revenue, remaining a backbone of many treatment regimens. Diffuse large B-cell lymphoma is the leading subtype with approximately 41.0% share, and follicular lymphoma is expected to grow fastest over the forecast period. Subcutaneous delivery is becoming more common as it reduces chair time and improves the patient experience. A deep clinical pipeline focused on novel mechanisms and combinations continues to shift standards of care and extend patient survival. Drivers: An important driver is the steady incidence of non-Hodgkin lymphoma across aging populations, since risk increases with age and the number of older adults continues to grow worldwide. The ongoing expansion of CAR T-cell therapy approvals and adoption is another key force, as these treatments move into earlier lines and more hospitals gain the capability to deliver them. Uptake of oral targeted agents, including BTK inhibitors, the introduction of bispecific antibodies, and more precise subtype diagnosis also support demand. Longer survival means many patients receive several lines of treatment, increasing overall therapy consumption. Business Opportunity: Innovation in follicular lymphoma treatment represents a major opportunity, as bispecific antibodies and other targeted approaches deliver better efficacy and convenience for this common indolent subtype. Developers of novel bispecific and cell-based therapies aimed at patients who relapse on, or are ineligible for, current treatments can meet significant unmet need in relapsed and refractory populations. Further growth potential lies in off-the-shelf allogeneic cell therapies, patient-friendly subcutaneous formulations, and wider access initiatives in emerging economies, where improvements in diagnostic capability and oncology care infrastructure are gradually expanding the treatable patient base. Region Analysis: North America dominates the global non-Hodgkin lymphoma therapeutics market, holding about 47.0% of revenue in 2026, driven by premium therapy pricing, fast adoption of new treatments, and extensive specialized oncology networks. Europe contributes close to 27.0%, supported by broad reimbursement for antibody therapies and increasing cell therapy use. Asia Pacific represents around 18.0% and is projected to be the fastest-growing region, as rising cancer incidence and expanding access to advanced oncology therapies gain pace in China, Japan, and South Korea. Latin America accounts for approximately 5.0% and Middle East & Africa about 3.0%, with growth supported by strengthening oncology infrastructure. Key Players: • Roche Holding AG • AbbVie Inc. • Bristol Myers Squibb Company • Gilead Sciences, Inc. • Novartis AG • Johnson & Johnson • AstraZeneca plc • Eli Lilly and Company • Regeneron Pharmaceuticals, Inc. • BeOne Medicines Ltd. Segmentation: By Drug Class • Monoclonal Antibodies • CAR T-Cell Therapies • BTK Inhibitors • Others By Lymphoma Subtype • Diffuse Large B-Cell Lymphoma (DLBCL) • Follicular Lymphoma • Mantle Cell Lymphoma • Others By Route of Administration • Intravenous • Subcutaneous By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Non-Hodgkin Lymphoma Therapeutics Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 3.1. Global Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 3.1.1. Monoclonal Antibodies 3.1.2. CAR T-Cell Therapies 3.1.3. BTK Inhibitors 3.1.4. Others 3.2. Global Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 3.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 3.2.2. Follicular Lymphoma 3.2.3. Mantle Cell Lymphoma 3.2.4. Others 3.3. Global Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 3.3.1. Intravenous 3.3.2. Subcutaneous 3.4. Global Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 4.1. North America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 4.1.1. Monoclonal Antibodies 4.1.2. CAR T-Cell Therapies 4.1.3. BTK Inhibitors 4.1.4. Others 4.2. North America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 4.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 4.2.2. Follicular Lymphoma 4.2.3. Mantle Cell Lymphoma 4.2.4. Others 4.3. North America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 4.3.1. Intravenous 4.3.2. Subcutaneous 4.4. North America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 4.4.2. U.S. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 4.4.3. U.S. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 4.4.4. Canada Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 4.4.5. Canada Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 4.4.6. Canada Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 5.1. Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 5.1.1. Monoclonal Antibodies 5.1.2. CAR T-Cell Therapies 5.1.3. BTK Inhibitors 5.1.4. Others 5.2. Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 5.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 5.2.2. Follicular Lymphoma 5.2.3. Mantle Cell Lymphoma 5.2.4. Others 5.3. Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 5.3.1. Intravenous 5.3.2. Subcutaneous 5.4. Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.2. Germany Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.3. Germany Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.4. Italy Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.5. Italy Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.6. Italy Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.7. France Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.8. France Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.9. France Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.10. U.K. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.11. U.K. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.12. U.K. Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.13. Spain Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.14. Spain Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.15. Spain Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.16. Russia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.17. Russia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.18. Russia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.4.19. Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 5.4.20. Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 5.4.21. Rest of Europe Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 6.1. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 6.1.1. Monoclonal Antibodies 6.1.2. CAR T-Cell Therapies 6.1.3. BTK Inhibitors 6.1.4. Others 6.2. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 6.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 6.2.2. Follicular Lymphoma 6.2.3. Mantle Cell Lymphoma 6.2.4. Others 6.3. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 6.3.1. Intravenous 6.3.2. Subcutaneous 6.4. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.2. China Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.3. China Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.4.4. Japan Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.5. Japan Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.6. Japan Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.4.7. South Korea Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.8. South Korea Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.9. South Korea Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.4.10. India Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.11. India Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.12. India Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.4.13. Southeast Asia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.14. Southeast Asia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.15. Southeast Asia Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.4.16. Rest of SAO Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 6.4.17. Rest of SAO Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 6.4.18. Rest of SAO Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 7.1. Latin America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 7.1.1. Monoclonal Antibodies 7.1.2. CAR T-Cell Therapies 7.1.3. BTK Inhibitors 7.1.4. Others 7.2. Latin America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 7.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 7.2.2. Follicular Lymphoma 7.2.3. Mantle Cell Lymphoma 7.2.4. Others 7.3. Latin America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 7.3.1. Intravenous 7.3.2. Subcutaneous 7.4. Latin America Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 7.4.2. Brazil Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 7.4.3. Brazil Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 7.4.4. Mexico Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 7.4.5. Mexico Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 7.4.6. Mexico Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 7.4.7. Argentina Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 7.4.8. Argentina Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 7.4.9. Argentina Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 7.4.10. Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 7.4.11. Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 7.4.12. Rest of LATAM Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, 2020-2033 8.1. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 8.1.1. Monoclonal Antibodies 8.1.2. CAR T-Cell Therapies 8.1.3. BTK Inhibitors 8.1.4. Others 8.2. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, Value (US$ Bn), 2020-2033 8.2.1. Diffuse Large B-Cell Lymphoma (DLBCL) 8.2.2. Follicular Lymphoma 8.2.3. Mantle Cell Lymphoma 8.2.4. Others 8.3. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 8.3.1. Intravenous 8.3.2. Subcutaneous 8.4. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 8.4.2. GCC Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 8.4.3. GCC Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 8.4.4. South Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 8.4.5. South Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 8.4.6. South Africa Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 8.4.7. Egypt Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 8.4.8. Egypt Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 8.4.9. Egypt Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 8.4.10. Nigeria Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 8.4.11. Nigeria Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 8.4.12. Nigeria Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 8.4.13. Rest of Middle East Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Drug Class, 2020-2033 8.4.14. Rest of Middle East Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Lymphoma Subtype, 2020-2033 8.4.15. Rest of Middle East Non-Hodgkin Lymphoma Therapeutics Market Outlook, by Route of Administration, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Roche Holding AG 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. AbbVie Inc. 9.4.3. Bristol Myers Squibb Company 9.4.4. Gilead Sciences, Inc. 9.4.5. Novartis AG 9.4.6. Johnson & Johnson 9.4.7. AstraZeneca plc 9.4.8. Eli Lilly and Company 9.4.9. Regeneron Pharmaceuticals, Inc. 9.4.10. BeOne Medicines Ltd. 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社の ヘルスケアIT分野 での最新刊レポート
本レポートと同じKEY WORD（lymphoma therapeutics）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
